Ajinomoto Bio-Pharma Services
https://ajibio-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ajinomoto Bio-Pharma Services
After Jounce, Concentra Pounces On Atea
Concentra's unsolicited bid for Atea is the latest proof that promising but financially strapped biotechs that are trading below cash are prime M&A targets.
Big Year Ahead For New Vir CEO De Backer
Having played a pivotal role in changing pharma strategy at Bayer, Marianne De Backer tells Scrip about her goal to turn Vir into an infectious disease powerhouse as the firm prepares for critical Phase II data readouts in hepatitis B and D, as well as flu.
Paxlovid Gets FDA Panel Backing For Full Approval; Combating Rebound Misperception Urged
Patient advocate is sole committee member to vote against Paxlovid favorable benefit-risk profile, saying doctors do not know how to use the treatment. Members suggest conducting natural history studies on COVID rebound and publishing data that shows no clear association with Paxlovid.
Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger
In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Althea Technologies, Inc.
- Ajinomoto Pharmaceuticals Co., Ltd.
- EA Pharma Co., Ltd.
- GeneDesign
- OmniChem
- Granules OmniChem Private Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice